Date: 2015-01-13
Type of information: Licensing agreement
Compound: OP0595
Company: Fedora Pharmaceuticals (Canada) Meiji Seika Pharma (Japan) Roche (Switzerland)
Therapeutic area: Infectious diseases
Type agreement: development licensing commercialisation
Action mechanism: OP0595 is a serine-β-lactamase inhibitor containing diazabicyclic skeleton. It acts in three ways: i) as a β-lactamase inhibitor, ii) as an antibiotic agent for Enterobacteriaceae, and iii) as an enhancer of activity of various β-lactam agents. OP0595 has been discovered by Meiji Seika Pharma.
Disease:
Details: * On January 13, 2015, Roche , Meiji Seika Pharma and Fedora Pharmaceuticals announced that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development. Under the agreement, Roche obtains worldwide rights from both companies for development and commercialization with the exception of Japan, where Meiji will retain sole commercialization rights. Beta-lactamase inhibitors restore or potentiate the activity of beta-lactam antibiotics. The combination of OP0595 with a beta-lactam antibiotic targets severe infections caused by Enterobacteriaceae, including multi-drug-resistant strains.
Financial terms: Under the terms of the agreement, Meiji and Fedora will receive upfront plus development, regulatory and sales event milestone payments totaling potentially up to $750 million. In addition, Meiji and Fedora are entitled to receive tiered royalties on sales of products originating from this collaboration.
Latest news:
